Drugs / PERFLUORO TERT-BUTYLCYCLOHEXANE
PERFLUORO TERT-BUTYLCYCLOHEXANE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00908063 | Oct 2009 → Sep 2014 | traumatic brain injury | Tenax Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00174980 | Sep 2005 → Mar 2008 | traumatic brain injury | Tenax Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Aurum Biosciences Ltd | Results Aurum Publishes Paper on ABL-101 Technology aurumbiosciences.com ↗
Additionally Aurum collected data suggesting potential therapeutic benefit to animals that had been treated with ABL-101 technology. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-06-04 | Aurum Biosciences Ltd | Aurum Publishes Paper on ABL-101 Technology aurumbiosciences.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERFLUORO TERT-BUTYLCYCLOHEXANE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297413 ↗ |
| Known as | Oxycyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00908063 ↗ |
| Known as | Perfluoro t-butylcyclohexane | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297413 ↗ |
| Modality | Other / unclassified | “Oxycyte™ Perfluorocarbon” NCT00174980 ↗ |
| Route | Intravenous | “single intravenous infusion of 3ml/kg of Oxycyte.” NCT00174980 ↗ |